多替拉韦对比利托那韦增强洛匹那韦联合双核苷逆转录酶抑制剂在成人HIV-1一线治疗失败后的疗效(DAWNING):开放标签、非劣效、3b期试验
DAWNING试验在13个国家58个中心纳入627例NNRTI+2NRTI一线治疗失败的HIV-1成人,随机接受多替拉韦或利托那韦增强洛匹那韦联合2种NRTI。
要点
- 多替拉韦联合2种NRTI在48周病毒抑制率优于利托那韦增强洛匹那韦方案。
- 多替拉韦组2-4级药物相关不良事件发生率低于洛匹那韦/利托那韦组。
- 多替拉韦可作为一线NNRTI方案失败后的二线治疗选择。
核心结论
- 多替拉韦联合两种NRTI在48周时病毒学抑制优于利托那韦增强洛匹那韦,可作为二线治疗合适选择。
研究设计与样本
- DAWNING为3b期、开放标签、平行组、非劣效、活性对照试验,在13个国家58个中心进行。
- 共筛查968例成人,随机分配627例(多替拉韦组312例,利托那韦增强洛匹那韦组315例),ITT-E人群624例。
- 纳入≥18岁、含NNRTI+2NRTI一线治疗至少6个月后确认HIV-1 RNA≥400 copies/mL的成人。
主要发现
- 第48周多替拉韦组261/312(84%)实现病毒抑制,利托那韦增强洛匹那韦组219/312(70%)实现病毒抑制。
- 利托那韦增强洛匹那韦组2-4级药物相关不良事件44/310(14%),多替拉韦组11/314(4%),主要为胃肠道疾病。
关键数值与推荐
- 主要终点为第48周血浆HIV-1 RNA<50 copies/mL的比例(snapshot算法),非劣效界值-12%。
- 多替拉韦剂量为50 mg每日一次口服;利托那韦增强洛匹那韦为800 mg洛匹那韦+200 mg利托那韦每日一次或400 mg+100 mg每日两次。
- 联合两种研究者选择的NRTI,至少一种基于筛查时耐药检测为完全活性。
临床怎么用
- 对于含NNRTI+2NRTI一线方案失败的HIV-1成人,可优先考虑多替拉韦联合两种NRTI作为二线治疗。
- 多替拉韦方案相较于利托那韦增强洛匹那韦方案具有更好的病毒学抑制和安全性。
局限性
- 开放标签设计可能影响不良事件报告。
- 研究在资源有限地区进行,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Doubts exist regarding optimal second-line treatment options for HIV-1-infected patients in resource-limited settings. We assessed safety and efficacy of dolutegravir compared with ritonavir-boosted lopinavir, plus two nucleoside reverse transcriptase inhibitors (NRTIs) in adults in whom previous first-line antiretroviral therapy with a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two NRTIs has failed. METHODS: DAWNING is a phase 3b, open-label, parallel-group, non-inferiority, active-controlled trial done at 58 sites in 13 countries. Eligible adults were aged at least 18 years and, during at least 6 months of treatment with a first-line treatment containing an NNRTI and two NRTIs, had virological failure (confirmed HIV-1 RNA ≥400 copies per mL). Participants were randomly assigned by a central randomisation system to receive oral dolutegravir (50 mg once daily) or ritonavir-boosted lopinavir (800 mg lopinavir plus 200 mg ritonavir once daily or 400 mg plus 100 mg twice daily), plus two investigator-selected NRTIs (at least one fully active based on resistance testing at screening). The primary outcome was the proportion of participants achieving viral suppression (defined as plasma HIV-1 RNA <50 copies per mL) at week 48 using the snapshot algorithm and a non-inferiority margin of -12%. The primary analysis was done in an intention-to-treat-exposed (ITT-E) population of participants who received at least one dose of study medication, according to original group assignment. Safety was analysed in all participants who received at least one dose of study drug, according to which drug was received. The study was registered at ClinicalTrials.gov, number NCT02227238, and viiv-studyregister.com, number 200304. FINDINGS: Between Dec 11, 2014, and June 27, 2016, 968 adults were screened and 627 were randomly assigned to the dolutegravir group (n=312) or the ritonavir-boosted lopinavir group (n=315). Three patients in the ritonavir-boosted lopinavir group did not receive study medication and so 624 were included in the ITT-E population. At week 48, 261 (84%) of 312 participants in the dolutegravir group achieved viral suppression compared with 219 (70%) of 312 in the ritonavir-boosted lopinavir group (adjusted difference 13·8%; 95% CI 7·3-20·3). Non-inferiority was achieved on the basis of the 95% CI of the adjusted treatment difference having a lower bound greater than -12% (prespecified non-inferiority margin). Because the lower bound of the 95% CI is greater than zero (7·3%), superiority of dolutegravir was also concluded (p<0·0001). The safety profile for dolutegravir was favourable compared with that of ritonavir-boosted lopinavir. More grade 2-4 drug-related adverse events occurred with ritonavir-boosted lopinavir than dolutegravir (44 [14%] of 310 with ritonavir-boosted lopinavir vs 11 [4%] of 314 with dolutegravir), mainly driven by gastrointestinal disorders. INTERPRETATION: When administered with two NRTIs, dolutegravir was superior to ritonavir-boosted lopinavir at 48 weeks and can be considered a suitable option for second-line treatment. FUNDING: ViiV Healthcare.
引用
- Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 2019. PMID: 30732940. doi:10.1016/S1473-3099(19)30036-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。